PhRMA: 92 HIV/AIDS prods in development
According to a report from the Pharmaceutical Research and Manufacturers of America (PhRMA), pharmaceutical researchers are currently testing 92 drugs and vaccines to treat or prevent HIV/AIDS and related conditions. This study was released ahead of December 1, which marks the 20th anniversary of World AIDS Day, a global awareness campaign that originated at the 1988 World Summit of Ministers of Health on Programs for AIDS Prevention, the association notes.
"We are greatly encouraged by the new, critically-important medicines and vaccines in development to treat and prevent HIV infection," says PhRMA chief executive Billy Tauzin. "Pharmaceutical researchers are continuing their efforts to develop new therapies and vaccines to improve and lengthen the lives of HIV-infected patients," he added.
The report says that, of the 92 products in development, researchers are studying 20 vaccines and 46 antivirals. These drugs are either in human clinical trials or await approval by the US Food and Drug Administration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze